Washington Trust Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Washington Trust Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-78	Closed	-$6.51K	–	671
2024 Q4	$6.51K	Hold	78	–	–	﹤0.01%	536
2024 Q3	$5.71K	Hold	78	–	–	﹤0.01%	554
2024 Q2	$5.34K	Hold	78	–	–	﹤0.01%	545
2024 Q1	$5.4K	Hold	78	–	–	﹤0.01%	563
2023 Q4	$5.59K	Hold	78	–	–	﹤0.01%	557
2023 Q3	$4.06K	Hold	78	–	–	﹤0.01%	574
2023 Q2	$4.94K	Hold	78	–	–	﹤0.01%	543
2023 Q1	$4.22K	Hold	78	–	–	﹤0.01%	633
2022 Q4	$4.13K	Hold	78	–	–	﹤0.01%	636
2022 Q3	$4K	Hold	78	–	–	﹤0.01%	780
2022 Q2	$4K	Hold	78	–	–	﹤0.01%	806
2022 Q1	$5K	Buy	+78	New	+$4.05K	﹤0.01%	836

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Washington Trust Advisors's ITCI Position: Q1 2025 in Review

Washington Trust Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 78 shares — an estimated $6.51K sold.

Washington Trust Advisors first reported a position in ITCI in Q1 2022 and held it in 12 quarters. The position peaked at $6.51K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Washington Trust Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Washington Trust Advisors sold 78 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $6.51K.
Washington Trust Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 12 quarters.
Washington Trust Advisors's Intra-Cellular Therapies Inc. position peaked at $6.51K in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Washington Trust Advisors's 13F filing for Q1 2025, filed 25 Apr 2025.